Morgan Stanley lowered the firm’s price target on Alignment Healthcare (ALHC) to $12 from $19 and keeps an Overweight rating on the shares. With Q2 earnings season now behind, the firm believes cost trend concerns have “significantly subsided,” helping to create a cleaner path forward to owning Managed Care stocks and grows increasingly positive on Elevance (ELV), its “Top Pick,” Humana (HUM) and Alignment Health, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALHC:
- Alignment Healthcare reports Q2 EPS (15c), consensus (22c)
- Alignment Healthcare Reports Second Quarter 2023 Results; Beats Outlook Across All Four Critical KPIs
- Alignment Healthcare Spotlights Improved Senior Health Outcomes, Greater Access to Care in 2nd Annual ESG Report
- Alignment Health Names Chief Legal and Administrative Officer
- Alignment Healthcare to Announce Second Quarter 2023 Financial Results and Host Conference Call Thursday, Aug. 3, 2023